# HEDIS PORTFOLIO OPTIMIZER - Q4 2024 EXECUTIVE SUMMARY

## PERFORMANCE HIGHLIGHTS

**Total Investment:** $227,719.00 | **Revenue Impact:** $293,800.00 | **Net Benefit:** $66,081.00 | **ROI:** 1.29x

**Successful Closures:** 2,938 | **Average Cost per Closure:** $77.51 | **Success Rate:** 42.4%

---

## TOP 3 PERFORMING MEASURES

| Rank | Measure | ROI | Investment | Closures | Cost/Closure |
|------|---------|-----|------------|----------|-------------|
| **1** | **BPD** - Blood Pressure Control | **1.38x** | $18,776.00 | 259 | $72.49 |
| **2** | **SUPD** - Emergency Follow-Up | **1.37x** | $16,570.00 | 227 | $73.00 |
| **3** | **BCS** - Breast Cancer Screening | **1.35x** | $13,300.00 | 179 | $74.30 |

---

## MOST COST-EFFECTIVE INTERVENTIONS

| Rank | Intervention | Cost/Closure | Success Rate |
|------|--------------|--------------|--------------|
| **1** | Automated Reminder System | **$6.00** | 44.4% |
| **2** | Member Portal Notification | **$12.00** | **48.5%** |
| **3** | Text Message | **$30.00** | 40.6% |

---

## MOST EXPENSIVE MEASURES

| Rank | Measure | Cost/Closure | Investment | Closures |
|------|---------|--------------|------------|----------|
| 1 | CBP - Controlling High Blood Pressure | $83.86 | $24,152.00 | 288 |
| 2 | COL - Colorectal Cancer Screening | $83.44 | $17,772.00 | 213 |
| 3 | GSD - Glycemic Status Assessment | $79.24 | $19,097.00 | 241 |

---

## BUDGET DISCIPLINE

**Total Budget:** $520,000.00 | **Total Spent:** $540,410.00 | **Utilization:** 103.9% | **Over Budget:** 8 of 12 measures

---

## BUSINESS IMPACT

In Q4 2024, investing **$227,719** across 12 HEDIS measures achieved **2,938 successful gap closures**, generating **$293,800 in revenue impact**. With a **1.29x ROI ratio** and **$66,081 net benefit**, this demonstrates data-driven decision-making and measurable business value in healthcare analytics.

**Key Achievements:** All 12 measures show positive ROI (1.19x - 1.38x) | 42.4% success rate | $77.51 avg cost/closure

**Strategic Insights:** Low-touch digital interventions deliver highest efficiency | BPD leads with 1.38x ROI | Budget variance enables proactive allocation

---

*Report Generated: November 19, 2025 | Period: Q4 2024 (Oct 1 - Dec 31, 2024)*

